4.6 Review

Virtual and Augmented Reality in Cardiovascular Care State-of-the-Art and Future Perspectives

期刊

JACC-CARDIOVASCULAR IMAGING
卷 15, 期 3, 页码 519-532

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcmg.2021.08.017

关键词

augmented reality; cardiovascular care; imaging; virtual reality

资金

  1. Abbott
  2. Edwards
  3. Daiichi Sankyo
  4. Boehringer Ingelheim
  5. CSL Behring
  6. Ferring Pharmaceuticals
  7. Bayer
  8. Afimmune
  9. Amarin
  10. Amgen
  11. AstraZeneca
  12. Bristol-Myers Squibb
  13. Cardax
  14. Chiesi
  15. Eisai
  16. Ethicon
  17. Forest Laboratories
  18. Fractyl
  19. Idorsia
  20. Ironwood
  21. Ischemix
  22. Lexicon
  23. Lilly
  24. Medtronic
  25. Pfizer
  26. PhaseBio
  27. PLx Pharma
  28. Regeneron
  29. Roche
  30. Sanofi Aventis
  31. Synaptic
  32. Medicines Company
  33. AliveCor

向作者/读者索取更多资源

Virtual reality and augmented reality have wide applications in cardiovascular education and treatment, with potential in various fields. However, there are technical challenges to overcome and ethical considerations to address, while ensuring the focus of physicians and patients.
Applications of virtual reality (VR) and augmented reality (AR) assist both health care providers and patients in cardiovascular education, complementing traditional learning methods. Interventionalists have successfully used VR to plan difficult procedures and AR to facilitate complex interventions. VR/AR has already been used to treat patients, during interventions in rehabilitation programs and in immobilized intensive care patients. There are numerous additional potential applications in the catheterization Laboratory. By using AR, interventionalists could combine visual fluoroscopy information projected and registered on the patient body with data derived from preprocedural imaging and live fusion of different imaging modalities such as fluoroscopy with echocardiography. Persistent technical challenges to overcome include the integration of different imaging modalities into VR/AR and the harmonization of data flow and interfaces. Cybersickness might exclude some patients and users from the potential benefits of VR/AR. Critical ethical considerations arise in the application of VR/AR in vulnerable patients. In addition, digital applications must not distract physicians from the patient. It is our duty as physicians to participate in the development of these innovations to ensure a virtual health reality benefit for our patients in a real-world setting. The purpose of this review is to summarize the current and future role of VR and AR in different fields within cardiology, its challenges, and perspectives. (C) 2022 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据